{
  "prompt": {
    "guidelineId": "sp22007-im-methotrexate-sop-and-competency-document-pdf",
    "fieldsProcessed": [
      "humanFriendlyName",
      "organisation",
      "yearProduced",
      "summary"
    ],
    "enhancedFields": 4,
    "contentLength": 5156
  },
  "response": "{\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Guidelines for Intramuscular Methotrexate in Ectopic Pregnancy and Trophoblastic Disease\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"RCOG\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The provided text does not contain a publication year. If you have another document or can provide the year, I'd be happy to extract it for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Intramuscular Methotrexate Clinical SOP for Ectopic Pregnancy/Persistent Trophoblastic Disease** **Purpose**: Ensure safe administration of IM Methotrexate for ectopic pregnancy or persistent gestational trophoblastic disease (PGTD). **Key Recommendations**: - **Ectopic Pregnancy**: Dose calculated as 50 mg/m² (BSA-based), with strict patient selection criteria. - **PGTD**: Chemotherapy may be required for molar pregnancies, with ongoing monitoring. - **Contraindications**: Allergy to Methotrexate, significant ectopic pain/bleeding, or abnormal renal/liver function. - **Informed Consent**: Mandatory before administration. - **Precautions**: Administering staff must not be pregnant; follow cytotoxic handling/disposal protocols. - **Side Effects**: Include injection site reactions, ulceration, bleeding, and photosensitivity. - **Administration**: Use Z-track technique in gluteus maximus; aspirate before injecting. - **Monitoring**: Track incidents and staff competency. **Procedure Steps**: 1. Verify prescription, patient details, and consent. 2. Administer via IM route using aseptic technique. 3. Dispose of waste in cytotoxic bins. 4. Manage spills with cytotoxic spill kit. **Competency**: Staff must complete training and demonstrate understanding of SOP before administering Methotrexate\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "endpoint": "enhanceGuidelineMetadata",
  "timestamp": "2025-06-18T23-04-36",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"guidelineId\": \"sp22007-im-methotrexate-sop-and-competency-document-pdf\",\n  \"fieldsProcessed\": [\n    \"humanFriendlyName\",\n    \"organisation\",\n    \"yearProduced\",\n    \"summary\"\n  ],\n  \"enhancedFields\": 4,\n  \"contentLength\": 5156\n}\n\nA: {\n  \"success\": true,\n  \"enhancedFields\": [\n    {\n      \"field\": \"humanFriendlyName\",\n      \"oldValue\": null,\n      \"newValue\": \"Guidelines for Intramuscular Methotrexate in Ectopic Pregnancy and Trophoblastic Disease\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"organisation\",\n      \"oldValue\": null,\n      \"newValue\": \"RCOG\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"yearProduced\",\n      \"oldValue\": null,\n      \"newValue\": \"The provided text does not contain a publication year. If you have another document or can provide the year, I'd be happy to extract it for you\",\n      \"action\": \"added\"\n    },\n    {\n      \"field\": \"summary\",\n      \"oldValue\": null,\n      \"newValue\": \"**Summary of Intramuscular Methotrexate Clinical SOP for Ectopic Pregnancy/Persistent Trophoblastic Disease** **Purpose**: Ensure safe administration of IM Methotrexate for ectopic pregnancy or persistent gestational trophoblastic disease (PGTD). **Key Recommendations**: - **Ectopic Pregnancy**: Dose calculated as 50 mg/m² (BSA-based), with strict patient selection criteria. - **PGTD**: Chemotherapy may be required for molar pregnancies, with ongoing monitoring. - **Contraindications**: Allergy to Methotrexate, significant ectopic pain/bleeding, or abnormal renal/liver function. - **Informed Consent**: Mandatory before administration. - **Precautions**: Administering staff must not be pregnant; follow cytotoxic handling/disposal protocols. - **Side Effects**: Include injection site reactions, ulceration, bleeding, and photosensitivity. - **Administration**: Use Z-track technique in gluteus maximus; aspirate before injecting. - **Monitoring**: Track incidents and staff competency. **Procedure Steps**: 1. Verify prescription, patient details, and consent. 2. Administer via IM route using aseptic technique. 3. Dispose of waste in cytotoxic bins. 4. Manage spills with cytotoxic spill kit. **Competency**: Staff must complete training and demonstrate understanding of SOP before administering Methotrexate\",\n      \"action\": \"added\"\n    }\n  ]\n}",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": null
}